BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock suffered a major decline of -10.1% on 12/6/23. The shares closed at $5.51. Moreover, exceptionally high trading volume at 489% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months but has risen 2.2% during the last week.
Current PriceTarget Research Rating
BCRX is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.